Reactive Oxygen Species (ROS), Nanoparticles, and Endoplasmic Reticulum (ER) Stress-Induced Cell Death Mechanisms presents the role of ROS?mediated pathways cellular signaling stress, endoplasmic reticulum (ER) stress, oxidative stress, oxidative damage, nanomaterials, and the mechanisms by which metalloids and nanoparticles induce their toxic effects. The book covers the ecotoxicology of environmental heavy metal ions and free radicals on macromolecules cells organisms, heavy metals?induced cell responses, oxidative stress, the source of oxidants, and the roles of ROS, oxidative stress and oxidative damage mechanisms. It also examines the nanotoxicity, cytotoxicity and genotoxicity mechanisms of nanomaterials and the effects of nanoparticle interactions. Antioxidant defense therapy and strategies for treatment round out the book, making it an ideal resource for researchers and professional scientists in toxicology, environmental chemistry, environmental science, nanomaterials and the pharmaceutical sciences.

Elsevier now offers a series of derivative works based on the acclaimed "Meyler s Side Effect of Drugs, 15th Edition." These individual volumes are grouped by specialty to benefit the practicing biomedical researcher and/or clinician.
This volume is essential for internal medicine physicians and general practitioners who prescribe antibiotic drugs, like penicillin and tetracycline that cure bacterial infections, and antiviral drugs used to treat patients with HIV and herpes viruses.
* The only drug guide that includes clinical case studies and expert analysis
* "UNIQUE " Features not only antimicrobial drugs, but also all other drugs that act in an anti-microbial manner
* Most complete cross referencing of drug-drug interactions available
* Latest content from the most highly regarded compilation of drug side effects: "Side Effects of Drugs Annual" serial"

This volume is designed to impart the fundamental concepts in experimental pharmacology, research methodology and biostatistics. Through this book, the readers will learn about different methods involved in drug discovery, experimental animals and their care, equipments and the various bioassays used in experimental pharmacology. This book contains special sections on various drug screening methods involved in the evaluation of different body systems. Certain sections provide the healthcare professionals with the knowledge necessary to interpret clinical research articles, design clinical studies, and learn essential concepts in biostatistics in an expedient and concise manner. Basic principles and applications of simple analytical methods employed in drug analysis are well written under one section. It focuses on the basic and advanced laboratory techniques and also on computer simulated data, written extensively under the Biostatistics section. The methods used for drug analysis have been described in adequate detail with cross-references for further studies and comprehension. Overall, the book is designed systematically with four broad sections with extensive subdivisions for easy tracking, interpretation, and understanding.

Proteins are exposed to various interfacial stresses during drug product development. They are subjected to air-liquid, liquid-solid, and, sometimes, liquid-liquid interfaces throughout the development cycle-from manufacturing of drug substances to storage and drug delivery. Unlike small molecule drugs, proteins are typically unstable at interfaces where, on adsorption, they often denature and form aggregates, resulting in loss of efficacy and potential immunogenicity. This book covers both the fundamental aspects of proteins at interfaces and the quantification of interfacial behaviors of proteins. Importantly, this book introduces the industrial aspects of protein instabilities at interfaces, including the processes that introduce new interfaces, evaluation of interfacial instabilities, and mitigation strategies. The audience that this book targets encompasses scientists in the pharmaceutical and biotech industry, as well as faculty and students from academia in the surface science, pharmaceutical, and medicinal chemistry areas.

Advances in Molecular Toxicology features the latest advances in all of the subspecialties of the broad area of molecular toxicology. Toxicology is the study of poisons and this series details the study of the molecular basis by which a vast array of agents encountered in the human environment and produced by the human body itself manifest themselves as toxins. Not strictly limited to documenting these examples the series is also concerned with the complex web of chemical and biological events that give rise to toxin-induced symptoms and disease. The new technologies that are being harnessed to analyze and understand these events will also be reviewed by leading workers in the field.
Advances in Molecular Toxicology will report progress in all aspects of these rapidly evolving molecular aspects of toxicology with a view toward detailed elucidation of both progress on the molecular level and on advances in technological approaches employed
* Cutting edge reviews by leading workers in the discipline.
* In depth dissection of molecular aspects of interest to a broad range of scientists, physisicans and any student in the allied disciplines.
* Leading edge applications of technological innovations in the chemistry, biochemistry and molecular medicine.

This book exposes the skyrocketing rate of antipsychotic drug prescriptions for children, identifies grave dangers when children's mental health care is driven by market forces, describes effective therapeutic care for children typically prescribed antipsychotics, and explains how to navigate a drug-fueled mental health system. Since 2001, there has been a dramatic increase in the use of antipsychotics to treat children for an ever-expanding list of symptoms. The prescription rate for toddlers, preschoolers, and middle-class children has doubled, while the prescribing rate for low-income children covered by Medicaid has quadrupled. In a majority of cases, these drugs are neither FDA-approved nor justified by research for the children's conditions. This book examines the reasons behind the explosion of antipsychotic drug prescriptions for children, spotlighting the historical and cultural factors as well as the role of the pharmaceutical industry in this trend; and discusses the ethical and legal responsibilities and ramifications for non-MDs-psychologists in particular-who work with children treated with antipsychotics. Contributors explain how the pharmaceutical industry has inserted itself into every step of medical education, rendering objectivity in the scientific understanding, use, and approvals of such drugs impossible. The text describes the relentless marketing behind the drug sales, even going as far as to provide coloring and picture books for children related to the drug at issue. Valuable information about legal recourse that families and therapists can take when their children or patients have been harmed by antipsychotic drugs and alternative approaches to working with children with emotional and behavioral challenges is also provided. A chapter on effective parenting coauthored by a leading parenting expert, Laura Berk Contributions by noted medical journalist Robert Whitaker, author of Anatomy of an Epidemic Information on legal issues by Harvard-educated lawyer Jim Gottstein Insights from former pharmaceutical industry insider, Gwen Olsen An examination of community approaches to children's mental health care by internationally known psychologist Stuart Shanker

Elsevier now offers a series of derivative works based on the acclaimed Meylers Side Effect of Drugs, 15th Edition. These individual volumes are grouped by specialty to benefit the practicing physician or health care clinician.

Each year, heart disease kills more people than cancer. Patients are treated by a variety of specialists and primary care practitioners, depending on the organ system involved. This volume enables practitioners to assess the adverse effects of the complete range of drugs used in cardiovascular medicine, including antihypertensive drugs, and drugs used in the treatment of heart failure, angina, angina pectoris, and cardiac arrhythmia and enable practitioners to prescribe preventative treatments with medications such as blood pressure reducers, aspirin, and cholesterol-lowering drugs, as well as drugs used for more aggressive therapy.

The material is drawn from the 15th edition of the internationally renowned encyclopedia, Meyler s Side Effects of Drugs, and the latest volumes in the companion series, Side Effects of Drugs Annuals. Drug names have usually been designated by their recommended or proposed International Non-proprietary Names (rINN or pINN); when those are not available, clinical names have been used. In some cases, brand names have been used.

This volume is critical for any health professional involved in the administration of cardiovascular mediations.
Surpasses the Physician s Desk Reference (c) by including clinical case studies and independent expert analysisComplete index of drug namesMost complete cross referencing of drug-drug interactions availableExtensive references to primary and secondary literatureAlso includes information on adverse effects in pregnancy

The book is divided into six sections:

Drugs used to treat hypertension, heart failure and angina pectorisDiuretics - a general introduction to their adverse effects, followed by monographs on individual drugsAntidysrhythmic drugs - a general introduction to their adverse effects, followed by monographs on individual drugsDrugs that act on the cerebral and peripheral circulationsAnticoagulants, thrombolytic agents, and anti-platelet drugsCardiovascular adverse effects of non-cardiovascular drugs "

Membrane proteins continue to be prime drug targets because they perform essential processes in the cell including controlling the flow of information and materials between cells and mediating activities like hormone action and nerve impulses. The study of membrane proteins could lead to new and improved pharmaceutical treatments for a wide range of illnesses such as heart disease, cystic fibrosis and depression.

This volume reviews the latest developments in the field.

* Discusses new discoveries, approaches, and ideas in the field of membrane proteins and reviews how they are being used to develop new drugs * Contributions from leading scholars and industry experts * Reference guide for researchers involved in molecular biology and related fields

AHFS Drug Information (R) 2022 contains the most dependable drug information available-all in one place. It is the most comprehensive evidence-based source of drug information complete with therapeutic guidelines and off-label uses. With expanded and revised content supported by more than 97,000 references and incorporating the advice of numerous subject matter experts, AHFS DI helps you protect your patients and your practice. Updates in the new edition: The latest information on COVID-19 vaccines and COVID-19 monoclonal antibodies available under FDA Emergency Use Authorizations (EUAs), including clinical considerations from the US Centers for Disease Control and Prevention (CDC), and National Institutes of Health (NIH). Information on patient selection and appropriate use of corticosteroids in the management of COVID-19 based on recent guidelines from NIH and the World Health Organization (WHO). Contemporary issues such as anticoagulant reversal strategies and use of direct oral anticoagulants versus warfarin for treatment of venous thromboembolism or atrial fibrillation. Current best practices such as reversal of neuromuscular blocking agents for prevention of postoperative residual neuromuscular blockade. Newly published information on breakthrough oncology drugs approved as part of the FDA's accelerated approval program. Expanded content on off-label uses, real-world data, and long-term clinical data. Updated information on pharmacogenomic considerations based on recommendations from the Clinical Pharmacogenetics Implementation Consortium (CPIC). Addition of 51 new molecular entities (NMEs) or new therapeutic biological products approved since January 2021.

Elsevier now offers a series of derivative works based on the acclaimed Meylers Side Effect of Drugs, 15th Edition. These individual volumes are grouped by specialty to benefit the practicing physician or health care clinician.

The unwarranted effects of medications used in psychiatry can adversely affect a treatment plan. This book is critical in helping psychiatrists and mental health professionals assess the adverse effects of drugs such as antidepressants, mood stabilizers, hypnosedatives, and antipsychotic drugs.

The material is drawn from the 15th edition of the internationally renowned encyclopedia, Meyler s Side Effects of Drugs, and the latest volumes in the companion series, Side Effects of Drugs Annuals. Drug names have usually been designated by their recommended or proposed International Non-proprietary Names (rINN or pINN); when those are not available, clinical names have been used. In some cases, brand names have been used.

This volume is critical for any health professional involved in the administration of psychiatric mediations.
Surpasses the Physician s Desk Reference (c) by including clinical case studies and independent expert analysis

Complete index of drug names

Most complete cross referencing of drug-drug interactions available

Extensive references to primary and secondary literature

Also includes information on adverse effects in pregnancy

The book is divided into six sections:

Antidepressants A general introduction to their adverse effects, followed by monographs on individual drugs and groups of drugs (including lithium)

Neuroleptic drugs A general introduction to their adverse effects, followed by monographs on individual drugs

Hypnosedatives - A general introduction to their adverse effects, followed by monographs on individual drugs

Drugs of abuse

Drugs used to treat Alzheimer s disease

Psychological and psychiatric adverse effects of non-psychoactive drugs "

"Meyler's Side Effects of Herbal Medicines," named to Doody's Core Titles for 2013, is a derivatrive work based onthe acclaimed "Meyler s Side Effect of Drugs, Fifteenth Edition." This book summarizes the adverse effects of a large range of herbal medicines and the active ingredients that they contain. It includes extensive lists of the families of plants that are used as herbal medicines, including the Latin names of genera and species as well as the common names of individual plants. It features not only herbal medicines but information on important compounds such as tropane alkaloids, cardiac glycosides, nicotine, and pyrolizidine alkaloids.

The book is divided into three separate sections: Family - Each monograph is organized under a family of plants (for example, Liliaceae) Genera - The various genera that are included under the family name are tabulated (for example, the family Liliaceae contains 94 genera) Species - In each monograph, some species are dealt with separately (for example, in Liliaceae, four species are included under their Latin names and major common names)

Each monograph includes the following information: Alternative common names Active ingredients Uses - both traditional and modern Adverse effects References

Drug names are designated by their recommended or proposed International Non-proprietary Names (rINN or pINN); when those are not available, clinical names or brand names are used.

The material is drawn from the fifteenth edition of the internationally renowned encyclopedia, "Meyler s Side Effects of Drugs, " and the latest volumes in the companion series, "Side Effects of Drugs Annuals."

This volume is critical for any health professional or homeopathic practitioner with an interest in herbal medicines.
Named to Doody s Core Titles 2013, a collection development tool for health sciences libraries of all sizes, by Doody EnterprisesSurpasses the Physician s Desk Reference (c) by including clinical case studies and independent expert analysis Complete index of drug names Most complete cross referencing of drug-drug interactions available"

For almost a decade, quantitative NMR spectroscopy (qNMR) has been established as valuable tool in drug analysis. In all disciplines, i. e. drug identification, impurity profiling and assay, qNMR can be utilized.
Separation techniques such as high performance liquid chromatography, gas chromatography, super fluid chromatography and capillary electrophoresis techniques, govern the purity evaluation of drugs. However, these techniques are not always able to solve the analytical problems often resulting in insufficient methods. Nevertheless such methods find their way into international pharmacopoeias. Thus, the aim of the book is to describe the possibilities of qNMR in pharmaceutical analysis.
Beside the introduction to the physical fundamentals and techniques the principles of the application in drug analysis are described: quality evaluation of drugs, polymer characterization, natural products and corresponding reference compounds, metabolism, and solid phase NMR spectroscopy for the characterization drug substances, e.g. the water content, polymorphism, and drug formulations, e.g. tablets, powders. This part is accompanied by more special chapters dealing with representative examples. They give more detailed information by means of concrete examples.
- combines theory, techniques, and concrete applications-all of which closely resemble the laboratory experience
- considers international pharmacopoeias, addressing the concern for licensing
- features the work of academics and researchers, appealing to a broad readership

This volume is designed to provide an understanding of current and potential therapies for osteoporosis. The opening chapter introduces the cells of bone and their interactions. Several following chapters describe factors affecting bone including systemic hormones with significant effects on bone, and local mediators including growth factors, prostaglandins, cytokines and chemokines. Topics that have commanded particular attention recently are calcium, FGF-23, nervous system bone interactions. Drugs that cause bone loss provide important information on mechanism as well as therapeutic considerations. An overview of the genetics of bone disorders and a discussion of the pathophysiology of osteoporosis establish the clinical context. The final chapters discuss current and potential osteoporosis treatments.

Saffron: The Age-Old Panacea in a New Light is the first book to detail the functions and effect of saffron in medicinal situations. This book explores the medicinal aspects of saffron and the effect saffron imparts on various diseases of the central nervous system, cardiovascular system, digestive system, locomotor system, urogenital system, eye, skin, and immune system, along with their mechanism of action. This perpetual bulb found mainly in Asia and Europe, Iran, India and Mediterranean countries has been shown to reduce seizures, delay convulsions, and as a neuroprotective agent against cerebral ischemia, brain damage, and Alzheimer's and Parkinson's disease. In addition, it also reduces depression, hypnosis and anxiety and enhances learning and memory skills.